Ziccum Past Earnings Performance
Past criteria checks 0/6
Ziccum's earnings have been declining at an average annual rate of -15.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 74.6% per year.
Key information
-15.6%
Earnings growth rate
1.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 74.6% |
| Return on equity | -998.9% |
| Net Margin | -437.1% |
| Next Earnings Update | 29 Jan 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ziccum makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6 | -25 | 30 | 0 |
| 30 Jun 24 | 8 | -23 | 29 | 0 |
| 31 Mar 24 | 9 | -20 | 28 | 0 |
| 31 Dec 23 | 6 | -21 | 27 | 0 |
| 30 Sep 23 | 5 | -22 | 25 | 0 |
| 30 Jun 23 | 2 | -24 | 26 | 0 |
| 31 Mar 23 | 1 | -27 | 27 | 0 |
| 31 Dec 22 | 0 | -29 | 28 | 0 |
| 30 Sep 22 | 0 | -27 | 26 | 0 |
| 30 Jun 22 | 0 | -26 | 25 | 0 |
| 31 Mar 22 | 0 | -23 | 22 | 0 |
| 31 Dec 21 | 0 | -21 | 20 | 0 |
| 30 Sep 21 | 0 | -18 | 17 | 0 |
| 30 Jun 21 | 0 | -18 | 18 | 0 |
| 31 Mar 21 | 0 | -18 | 17 | 0 |
| 31 Dec 20 | 0 | -17 | 17 | 0 |
| 30 Sep 20 | 0 | -17 | 17 | 0 |
| 30 Jun 20 | 0 | -13 | 13 | 0 |
| 31 Mar 20 | 1 | -11 | 11 | 0 |
| 31 Dec 19 | 1 | -9 | 9 | 0 |
| 30 Sep 19 | 1 | -7 | 6 | 0 |
| 30 Jun 19 | 1 | -8 | 5 | 0 |
| 31 Mar 19 | 0 | -6 | 2 | 0 |
| 31 Dec 18 | 0 | -5 | 0 | 0 |
Quality Earnings: ZICC is currently unprofitable.
Growing Profit Margin: ZICC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZICC is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.
Accelerating Growth: Unable to compare ZICC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZICC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: ZICC has a negative Return on Equity (-998.93%), as it is currently unprofitable.